B
Bull
Bull · 25%HLXB
$11.72
情景价格
$9.900
-0.157 (-1.59%)收盘时
Loading chart…
- High
- 10.090
- Open
- 10.090
- VWAP
- 9.86
- Vol
- 129.30K
- Mkt Cap
- —
- Low
- 9.600
- Amount
- 1.28M
- EV/EBITDA, TTM
- 0.00
Helix Acquisition Corp. II is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. It has entered into a business combination agreement with TheRas, Inc., doing business as BridgeBio Oncology Therapeutics. Upon closing of the transaction, the combined company will be renamed BridgeBio Oncology Therapeutics, Inc.
估值指标
The current forward P/E ratio for Helix Acquisition Corp II (HLXB) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for HLXB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件时间线
资讯
8.508-06NewsfilterHelix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics
- 8.507-11Newsfilter
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination
8.502-28SeekingAlphaBridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II
- 8.5Newsfilter
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics
- 8.5Newsfilter
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines
HLXB FAQ — answered by Alphio AI
Helix Acquisition Corp. II is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. It has entered into a business combination agreement with TheRas, Inc., doing business as BridgeBio Oncology Therapeutics. Upon closing of the transaction, the combined company will be renamed BridgeBio Oncology Therapeutics, Inc. It operates in the Financials sector.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。